Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New surveys find payers and providers want more data from biopharmaceutical companies

By Joe Vandigo  |    December 6, 2017
Both payers and providers are interested in additional information from biopharmaceutical companies about prescription medicines – including information about pipeline medicines and unapproved...   Read More

How modernizing FDA regulations can benefit patients, providers and payers

By Andrew Powaleny  |    September 1, 2016
Yesterday, the U.S. Food and Drug Administration (FDA) announced a two-day hearing slated for November 9 and 10, seeking public input as the agency works to review and potentially revise its...   Read More

Guest Post: New bioethical Points to Consider on truthful and non-misleading product communication

By Guest Contributor  |    August 4, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

PhRMA & BIO release joint principles on communications with health care professionals and payers

By Jeff Francer  |    July 27, 2016
This blog post is authored by Jeffrey Francer (PhRMA) and Deborah Shelton (BIO). We are in an era of data-driven medicine. Patients, caregivers, health care professionals and insurers want more...   Read More

Fact Check Friday: Biopharmaceutical company communications with payers

By Andrew Powaleny  |    April 29, 2016
Today, we’re examining how and what biopharmaceutical companies communicate with payers about a medicine prior to its approval by the U.S. Food and Drug Administration (FDA). MYTH:...   Read More

Growing consensus on the need to improve communications with health care professionals

By Mit Spears  |    March 3, 2016
Today, the wealth of information about medicines is more comprehensive and complex than ever before. Scientific knowledge and new findings go far beyond the parameters established by Food and Drug...   Read More

Pacira settlement important step towards ensuring clinicians have access to the best available data on FDA-approved medicines

By Mit Spears  |    December 22, 2015
During last week’s FDA/CMS Summit for Biopharma Executives, I had the opportunity to discuss the many recent legal and regulatory developments regarding communicating scientific data and clinical...   Read More

ICYMI: Physicians want better information sharing with biopharmaceutical companies

By Mit Spears  |    November 23, 2015
The issue and debate around communications with health care professionals is at its very essence, a conversation about ensuring physicians have the best possible data to effectively treat...   Read More

The Pacira Case Study: Patients are better served when health care professionals have the most accurate and up-to-date medical information

By Mit Spears  |    November 13, 2015
Patients are better served when health care professionals have the most accurate and up-to-date medical information. This is true for data and information regarding FDA-approved uses and medically...   Read More

The drug development and approval process is about much more than the final “okay”

By Tina Stow  |    August 24, 2015
A recent Forbes story not only presents an oddly limited look at the U.S.’s drug development process, it also sends a misleading message to America’s patients and health care professionals. “The...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates